Therapy management from the point of view of improving prognosis

Renal cell carcinoma is one of the common malignant tumors of the kidney, accounts for about 3% of all tumor cases, and the rate of new cases is increasing. In terms of drug treatment options, this tumor entity has undergone more rapid change in recent years than almost any other malignant disease. Meanwhile, the focus is not only on targeted therapy in advanced renal cell carcinoma, but also on combination treatments.